What is ICU's current stock price?

ICU (SeaStar Medical Holding Corporation) is currently trading at $3.75 with a market cap of $10.6M.

What sector is SeaStar Medical Holding Corporation in?

SeaStar Medical Holding Corporation (ICU) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ICU a good stock to buy?

Analysts have a Buy consensus on ICU with a price target of $8.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ICU SeaStar Medical Holding Corporation

Healthcare

$3.75-5.30%ClosedMarket Cap: $10.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

20.09

P/S

7.41

EV/EBITDA

-0.14

DCF Value

$3.63

FCF Yield

-128.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

93.1%

Operating Margin

-832.5%

Net Margin

-828.6%

ROE

-146.3%

ROA

-105.6%

ROIC

-156.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$495.0K	$-3.5M	$—
Q4 null	$420.0K	$-2.9M	$—
FY null	$1.2M	$-12.2M	$—
Q3 null	$183.0K	$-3.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$8.00

Target (Median)

$8.00

Target Range

$8.00 - $8.00

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Maxim GroupBuy

2026-05-14

Trading Activity

Insider Trades

View All

Vincent Bernadette Ndirector

SellTue Feb 10

Van Heel Kennethdirector

SellTue Feb 10

Towne Bradford Kofficer: Principal Accounting Officer

SellTue Feb 10

Schlorff Ericofficer: Chief Executive Officer

SellTue Feb 10

Neuman Johndirector

SellTue Feb 10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-1.02

SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

Peers